冲击剂量与非冲击剂量糖皮质激素治疗特发性肺纤维化急性加重
该回顾性研究纳入2013年1月至2021年12月单中心238例接受糖皮质激素治疗的AE-IPF患者,按住院7天内是否使用冲击剂量(甲泼尼龙≥250 mg/天或等效剂量)分为冲击组59例与非冲击组179例。多变量回归和倾向评分匹配分析显示,冲击剂量未降低3个月(aHR 0.84,95%CI 0.45-1.38)或12个月(aHR 0.96,95%CI 0.60-1.25)死亡风险。
要点
- 冲击剂量糖皮质激素未改善AE-IPF患者3个月和12个月生存。
- 冲击方案定义为住院7天内甲泼尼龙≥250 mg/天或等效剂量。
- 初始激素最佳剂量尚需前瞻性研究确定。
核心结论
- 冲击剂量糖皮质激素治疗AE-IPF的生存结局与非冲击常规剂量无差异。
- 需进一步前瞻性研究确定AE-IPF糖皮质激素的最佳初始剂量。
研究设计与样本
- 单家三级转诊医院回顾性分析,纳入2013年1月至2021年12月238例接受糖皮质激素治疗的AE-IPF患者。
- 按住院7天内是否使用冲击剂量(甲泼尼龙≥250 mg/天或等效)分为冲击组59例与非冲击组179例。
- 采用多变量回归和倾向评分匹配分析比较两组生存结局。
主要发现
- 调整基线临床和影像严重度混杂因素后,冲击组3个月死亡风险aHR 0.84(95%CI 0.45-1.38)。
- 冲击组12个月死亡风险aHR 0.96(95%CI 0.60-1.25)。
- 倾向评分匹配分析结果与上述一致。
关键数值与推荐
- 冲击剂量定义:住院7天内甲泼尼龙≥250 mg/天或等效剂量。
- 238例中59例接受冲击剂量,179例接受常规非冲击剂量。
临床怎么用
- AE-IPF初始激素剂量选择缺乏证据支持冲击方案常规使用。
- 临床决策应结合个体情况,不宜以冲击剂量作为默认策略。
局限性
- 为单中心回顾性研究,存在选择偏倚等回顾性设计固有局限。
- 样本量有限,冲击组仅59例。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND OBJECTIVE: Corticosteroids are commonly used for the treatment of acute exacerbation of idiopathic pulmonary fibrosis (AE-IPF); however, the optimal initial dose of corticosteroids remains uncertain due to a lack of sufficient evidence. We evaluated whether the administration of a pulse dose of corticosteroids resulted in improved survival outcomes compared with conventional non-pulse dose of corticosteroids. METHODS: We retrospectively analysed 238 patients with AE-IPF treated with corticosteroids at a tertiary referral hospital between January 2013 and December 2021. Based on whether a pulse dose of corticosteroids (methylprednisolone of ≥250 mg/day or equivalent) was administered within 7 days of hospitalization for AE-IPF, the patients were divided into the pulse and non-pulse regimen groups. The survival outcomes were compared between the two groups using multivariable regression and propensity score-matched analyses. RESULTS: Among the 238 patients, 59 patients received pulse dose of corticosteroids, whereas 179 patients received conventional non-pulse dose of corticosteroids. After adjusting for the confounding factors related to the baseline clinical and radiographic severity, compared with the conventional non-pulse regimen, the pulse regimen of corticosteroids did not reduce the risk of mortality at the 3-month (aHR 0.84, 95% CI 0.45-1.38) or 12-month (aHR 0.96, 95% CI 0.60-1.25) follow-ups. Propensity score-matched analysis revealed similar results. CONCLUSION: The survival outcomes of patients with AE-IPF who received a pulse dose of corticosteroids did not differ from those of patients who received conventional non-pulse dose of corticosteroids. Further prospective studies are required to establish the optimal initial dose of corticosteroids for the treatment of AE-IPF.
引用
- Hyung K, Lee JH, Kim JY, et al. Pulse versus non-pulse corticosteroid therapy in patients with acute exacerbation of idiopathic pulmonary fibrosis. Respirology. 2023. PMID: 38087838. doi:10.1111/resp.14643
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。